vs
Side-by-side financial comparison of Merck & Co. (MRK) and Wells Fargo (WFC). Click either name above to swap in a different company.
Wells Fargo is the larger business by last-quarter revenue ($21.3B vs $16.4B, roughly 1.3× Merck & Co.). Wells Fargo runs the higher net margin — 25.2% vs 18.1%, a 7.1% gap on every dollar of revenue. On growth, Merck & Co. posted the faster year-over-year revenue change (5.0% vs 4.5%). Over the past eight quarters, Merck & Co.'s revenue compounded faster (2.0% CAGR vs 1.0%).
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fourth on the list of largest biomedical companies by revenue.
Wells Fargo & Company is an American multinational financial services company. The company operates in 35 countries and serves more than 70 million customers worldwide. It is a systemically important financial institution according to the Financial Stability Board, and is considered one of the "Big Four Banks" in the United States, alongside JPMorgan Chase, Bank of America, and Citigroup.
MRK vs WFC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.4B | $21.3B |
| Net Profit | $3.0B | $5.4B |
| Gross Margin | 66.2% | — |
| Operating Margin | 20.9% | 30.7% |
| Net Margin | 18.1% | 25.2% |
| Revenue YoY | 5.0% | 4.5% |
| Net Profit YoY | -20.8% | 5.6% |
| EPS (diluted) | $1.19 | $1.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.4B | $21.3B | ||
| Q3 25 | $17.3B | $21.4B | ||
| Q2 25 | $15.8B | $20.8B | ||
| Q1 25 | $15.5B | $20.1B | ||
| Q4 24 | $15.6B | $20.4B | ||
| Q3 24 | $16.7B | $20.4B | ||
| Q2 24 | $16.1B | $20.7B | ||
| Q1 24 | $15.8B | $20.9B |
| Q4 25 | $3.0B | $5.4B | ||
| Q3 25 | $5.8B | $5.6B | ||
| Q2 25 | $4.4B | $5.5B | ||
| Q1 25 | $5.1B | $4.9B | ||
| Q4 24 | $3.7B | $5.1B | ||
| Q3 24 | $3.2B | $5.1B | ||
| Q2 24 | $5.5B | $4.9B | ||
| Q1 24 | $4.8B | $4.6B |
| Q4 25 | 66.2% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 77.5% | — | ||
| Q1 25 | 78.0% | — | ||
| Q4 24 | 75.5% | — | ||
| Q3 24 | 75.5% | — | ||
| Q2 24 | 76.8% | — | ||
| Q1 24 | 77.6% | — |
| Q4 25 | 20.9% | 30.7% | ||
| Q3 25 | 39.0% | 32.2% | ||
| Q2 25 | 31.6% | 30.9% | ||
| Q1 25 | 38.0% | 26.4% | ||
| Q4 24 | 26.7% | 26.4% | ||
| Q3 24 | 24.6% | 30.6% | ||
| Q2 24 | 37.3% | 29.8% | ||
| Q1 24 | 35.9% | 26.8% |
| Q4 25 | 18.1% | 25.2% | ||
| Q3 25 | 33.5% | 26.1% | ||
| Q2 25 | 28.0% | 26.4% | ||
| Q1 25 | 32.7% | 24.3% | ||
| Q4 24 | 24.0% | 24.9% | ||
| Q3 24 | 19.0% | 25.1% | ||
| Q2 24 | 33.9% | 23.7% | ||
| Q1 24 | 30.2% | 22.1% |
| Q4 25 | $1.19 | $1.61 | ||
| Q3 25 | $2.32 | $1.66 | ||
| Q2 25 | $1.76 | $1.60 | ||
| Q1 25 | $2.01 | $1.39 | ||
| Q4 24 | $1.49 | $1.42 | ||
| Q3 24 | $1.24 | $1.42 | ||
| Q2 24 | $2.14 | $1.33 | ||
| Q1 24 | $1.87 | $1.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.6B | — |
| Total DebtLower is stronger | — | $174.7B |
| Stockholders' EquityBook value | $52.6B | $181.1B |
| Total Assets | $136.9B | $2148.6B |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.6B | — | ||
| Q3 25 | $18.2B | — | ||
| Q2 25 | $8.6B | — | ||
| Q1 25 | $9.2B | — | ||
| Q4 24 | $13.7B | — | ||
| Q3 24 | $14.6B | — | ||
| Q2 24 | $11.4B | — | ||
| Q1 24 | $5.6B | — |
| Q4 25 | — | $174.7B | ||
| Q3 25 | — | $177.8B | ||
| Q2 25 | — | $176.2B | ||
| Q1 25 | — | $173.7B | ||
| Q4 24 | — | $173.1B | ||
| Q3 24 | — | $182.0B | ||
| Q2 24 | — | $179.1B | ||
| Q1 24 | — | $187.8B |
| Q4 25 | $52.6B | $181.1B | ||
| Q3 25 | $51.9B | $181.2B | ||
| Q2 25 | $49.0B | $181.1B | ||
| Q1 25 | $48.3B | $181.1B | ||
| Q4 24 | $46.3B | $179.1B | ||
| Q3 24 | $44.5B | $183.3B | ||
| Q2 24 | $43.6B | $176.4B | ||
| Q1 24 | $40.4B | $180.9B |
| Q4 25 | $136.9B | $2148.6B | ||
| Q3 25 | $129.5B | $2062.9B | ||
| Q2 25 | $117.5B | $1981.3B | ||
| Q1 25 | $115.1B | $1950.3B | ||
| Q4 24 | $117.1B | $1929.8B | ||
| Q3 24 | $117.5B | $1922.1B | ||
| Q2 24 | $112.6B | $1940.1B | ||
| Q1 24 | $105.8B | $1959.2B |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.98× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | 0.96× | ||
| Q4 24 | — | 0.97× | ||
| Q3 24 | — | 0.99× | ||
| Q2 24 | — | 1.02× | ||
| Q1 24 | — | 1.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.9B | $4.1B |
| Free Cash FlowOCF − Capex | $1.8B | — |
| FCF MarginFCF / Revenue | 11.1% | — |
| Capex IntensityCapex / Revenue | 6.3% | — |
| Cash ConversionOCF / Net Profit | 0.96× | 0.77× |
| TTM Free Cash FlowTrailing 4 quarters | $12.4B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.9B | $4.1B | ||
| Q3 25 | $7.8B | $-869.0M | ||
| Q2 25 | $3.3B | $-11.2B | ||
| Q1 25 | $2.5B | $-11.0B | ||
| Q4 24 | $3.5B | $8.9B | ||
| Q3 24 | $9.3B | $4.2B | ||
| Q2 24 | $5.6B | $2.0B | ||
| Q1 24 | $3.1B | $-12.1B |
| Q4 25 | $1.8B | — | ||
| Q3 25 | $6.8B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $8.5B | — | ||
| Q2 24 | $4.8B | — | ||
| Q1 24 | $2.2B | — |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 39.6% | — | ||
| Q2 25 | 16.0% | — | ||
| Q1 25 | 7.5% | — | ||
| Q4 24 | 16.1% | — | ||
| Q3 24 | 51.1% | — | ||
| Q2 24 | 30.1% | — | ||
| Q1 24 | 14.1% | — |
| Q4 25 | 6.3% | — | ||
| Q3 25 | 5.7% | — | ||
| Q2 25 | 4.8% | — | ||
| Q1 25 | 8.6% | — | ||
| Q4 24 | 6.0% | — | ||
| Q3 24 | 4.7% | — | ||
| Q2 24 | 4.9% | — | ||
| Q1 24 | 5.5% | — |
| Q4 25 | 0.96× | 0.77× | ||
| Q3 25 | 1.35× | -0.16× | ||
| Q2 25 | 0.74× | -2.04× | ||
| Q1 25 | 0.49× | -2.26× | ||
| Q4 24 | 0.92× | 1.75× | ||
| Q3 24 | 2.94× | 0.82× | ||
| Q2 24 | 1.03× | 0.42× | ||
| Q1 24 | 0.65× | -2.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MRK
| Pharmaceuticalsegment | $8.7B | 53% |
| Keytruda | $4.9B | 30% |
| Other | $2.7B | 16% |
| Janumet | $57.0M | 0% |
| Isentress Isentress HD | $38.0M | 0% |
| Pifeltro | $25.0M | 0% |
| Belsomra | $23.0M | 0% |
| Dificid | $17.0M | 0% |
| Delstrigo | $14.0M | 0% |
| Lagevrio | $12.0M | 0% |
| Pneumovax23 | $4.0M | 0% |
WFC
| Other | $5.2B | 24% |
| Wealth And Investment Management | $3.4B | 16% |
| Investment Advisory Management And Administrative Service | $2.8B | 13% |
| Corporate And Investment Banking | $2.5B | 12% |
| Consumer Banking And Lending | $2.0B | 10% |
| Commercial Portfolio Segment | $1.1B | 5% |
| Commercial Banking | $1.1B | 5% |
| Credit Card Rewards And Rebates | $859.0M | 4% |
| Investment Advice | $716.0M | 3% |
| Deposit Account | $692.0M | 3% |
| Commissions And Brokerage Service Fees | $657.0M | 3% |
| Trailing Commission | $250.0M | 1% |
